Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.1
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 25895136
González-Prieto R, et al. (2015) c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4. Cell Cycle 14, 1859-72 25895136
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

K52-sm - Myc (human)
Modsite: PSEDIWkkFELLPtP SwissProt Entrez-Gene
Orthologous residues
Myc (human): K52‑sm, Myc iso2 (human): K67‑sm, Myc (mouse): K52‑sm, Myc (rat): K52‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited

K148-sm - Myc (human)
Modsite: AAkLVSEkLAsYQAA SwissProt Entrez-Gene
Orthologous residues
Myc (human): K148‑sm, Myc iso2 (human): K163‑sm, Myc (mouse): K149‑sm, Myc (rat): K149‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited

K157-sm - Myc (human)
Modsite: AsYQAARkDSGsPNP SwissProt Entrez-Gene
Orthologous residues
Myc (human): K157‑sm, Myc iso2 (human): K172‑sm, Myc (mouse): K158‑sm, Myc (rat): K158‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited

K317-sm - Myc (human)
Modsite: AAPPSTRkDYPAAkR SwissProt Entrez-Gene
Orthologous residues
Myc (human): K317‑sm, Myc iso2 (human): K332‑sm, Myc (mouse): K317‑sm, Myc (rat): K317‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited

K323-sm - Myc (human)
Modsite: RkDYPAAkRVkLDsV SwissProt Entrez-Gene
Orthologous residues
Myc (human): K323‑sm, Myc iso2 (human): K338‑sm, Myc (mouse): K323‑sm, Myc (rat): K323‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited

K326-sm - Myc (human)
Modsite: YPAAkRVkLDsVRVL SwissProt Entrez-Gene
Orthologous residues
Myc (human): K326‑sm, Myc iso2 (human): K341‑sm, Myc (mouse): K326‑sm, Myc (rat): K326‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited

K389-sm - Myc (human)
Modsite: PELENNEkAPkVVIL SwissProt Entrez-Gene
Orthologous residues
Myc (human): K389‑sm, Myc iso2 (human): K404‑sm, Myc (mouse): K389‑sm, Myc (rat): K389‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited

K392-sm - Myc (human)
Modsite: ENNEkAPkVVILKkA SwissProt Entrez-Gene
Orthologous residues
Myc (human): K392‑sm, Myc iso2 (human): K407‑sm, Myc (mouse): K392‑sm, Myc (rat): K392‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited

K398-sm - Myc (human)
Modsite: PkVVILKkAtAYILs SwissProt Entrez-Gene
Orthologous residues
Myc (human): K398‑sm, Myc iso2 (human): K413‑sm, Myc (mouse): K398‑sm, Myc (rat): K398‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited

K430-sm - Myc (human)
Modsite: RREQLKHkLEQLRNS SwissProt Entrez-Gene
Orthologous residues
Myc (human): K430‑sm, Myc iso2 (human): K445‑sm, Myc (mouse): K430‑sm, Myc (rat): K430‑sm
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mass spectrometry, mutation of modification site, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  HeLa (cervical), U2OS (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
DESUMOYLASE SENP2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
SUMO LIGASE PIAS1 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme
DESUMOYLASE SENP1 (human) siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease PIAS1 shRNA
siRNA increase SENP1 shRNA
Downstream Regulation
Effect of modification (function):  protein degradation, ubiquitination
Effect of modification (process):  transcription, inhibited